SOLO3 Examines Benefit of Olaparib vs Chemo in Platinum-Sensitive Relapsed Ovarian Cancer
June 5, 2019 8:00 pmPatients with BRCA-mutated, platinum-sensitive relapsed ovarian cancer derived significant clinical benefit from treatment with olaparib monotherapy compared with treatment of physician’s choice, according to the results of the SOLO3 trial, a US Food and Drug Administration … Read more